ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

LATISSE
Miscellaneous dermatological conditions
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

LATISSE Rx

Generic Name and Formulations:
Bimatoprost 0.03%; oph soln; contains benzalkonium chloride.

Company:
Allergan

Therapeutic Use:

Indications for LATISSE:

Hypotrichosis of the eyelashes.

Adult:

1 drop once nightly; apply evenly along upper eyelid skin margin at the base of eyelashes. Repeat for opposite eyelid margin with new sterile applicator. Blot any excess solution runoff.

Children:

Not recommended.

Warnings/Precautions:

Do not apply to lower eyelash line. Repeated contact with bimatoprost outside the treatment area may cause hair growth. Ocular hypertension; monitor for changes to intraocular pressure. Ocular inflammation (eg, uveitis). Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15 minutes after administration). Pregnancy (Cat.C). Nursing mothers.

Interactions:

Concomitant with other intraocular pressure (IOP)-lowering prostaglandin analogues may decrease IOP-lowering effects.

Pharmacological Class:

Prostaglandin analogue.

Adverse Reactions:

Eye pruritus, conjunctival hyperemia, increased ocular pigmentation (iris, eyelid; may be permanent), ocular irritation, dry eye, erythema of the eyelid, macular edema, abnormal hair growth.

How Supplied:

Soln—3mL (w. disposable sterile applicators)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs